The major factors for the growth of the allergy treatment market include the increasing burden of various types of allergies, increased investment by the manufacturers on the development of novel allergic treatments and rising importance for self-medication.
The rising cases of allergies are expected to increase the demand of allergy immunotherapy, leading to the high growth of the market over the forecast period. According to the International Study of Asthma and Allergies in Childhood (ISAAC), about 22.1% of young children aged between 13 and 14 years are affected by hay fever, which was globally published in World Allergy Week 2016 fact sheet. As per the data published by the American College of Allergy, Asthma & Immunology, allergies are the sixth leading cause of chronic illness in the United States, with an annual cost in excess of USD 18 billion, and more than 50 million Americans suffer from allergies each year. There is an increase in the number of people suffering from food allergies among both children and adults, globally. Hence, the increasing burden of allergic diseases is expected to aid the demand for allergy treatment.
Key Market Trends Subcutaneous Immunotherapy (SCIT) is Expected to Register a High Growth Rate
The subcutaneous immunotherapy (SCIT), is the most commonly used and most effective form of allergy immunotherapy and it is the only treatment available that actually changes the immune system, making it possible to prevent the development of new allergies and asthma. The rising approval of immunotherapy is the major factor driving the growth of the market. For instance, recently, in 2018, one of the major market players, Stallergenes Greer received approval from the United States Food and Drug Administration (FDA) for the extension of the indication for Oralair, an allergy immunotherapy sublingual tablet, to treat patients ages 5 to 9 with grass pollen-induced allergic rhinitis. Furthermore, governments are taking initiatives to increase the awareness about allergies among the population, for instance recently, in January 2018, the Ministry and the Japanese Society of Allergology opened a dedicated website about allergies. Thus, owing to the rising burden of allergies and awareness among the population the market is expected to witness high growth.
North America is Expected to Dominate the Market
According to an article by Ruchi Gupta et al. published in JAMA Network Open Journal, an estimated 10.8% were food allergic at the time of the survey, whereas nearly 19% of adults believed that they were food allergic. Nearly half of food-allergic adults had at least 1 adult-onset food allergy, and 38% reported at least 1 food allergy-related emergency department visit in their lifetime.
This prevalence is very high. However, the United States has a very developed healthcare System. It also invests large amounts into research and development. Hence, US healthcare has the ability to provide treatment to nearly all of its popualtion. Hence the US allergy treatment market is expected to cover a large share of the market.
Competitive Landscape The majority of the allergy treatment products are being manufactured by the global key players. The market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness and this has also helped the market to grow.
Reasons to Purchase this report: - The market estimate (ME) sheet in Excel format - 3 months of analyst support
Our reports have been used by over 10K customers, including:
House Dust Mite Allergy - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2020, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape. House dust mite allergy is an...
Rhino-Conjunctivitis Global Clinical Trials Review, H2, 2020 Summary Clinical trial report, “Rhino-Conjunctivitis Global Clinical Trials Review, H2, 2020" provides an overview of Rhino-Conjunctivitis Clinical trials scenario.This report provides top line data relating to the clinical trials on Rhino-Conjunctivitis. Report...
Allergic Rhino-Conjunctivitis Global Clinical Trials Review, H1, 2020 Summary This clinical trial report, “Allergic Rhino-Conjunctivitis Global Clinical Trials Review, H1, 2020" provides an overview of Allergic Rhino-Conjunctivitis Clinical trials scenario.This report provides top line data relating...
Toll Like Receptor 4 - Pipeline Review, H1 2020 Summary According to the recently published report ’Toll Like Receptor 4 – Pipeline Review, H1 2020’; Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 44 molecules. Out of which approximately 35 molecules are developed...
Peanut Allergy - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H1 2020, provides an overview of the Peanut Allergy (Immunology) pipeline landscape. Peanut allergy is common, especially in children. An allergic...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.